A proof-of-concept study to assess the putative dose response to topical corticosteroid in persistent allergic rhinitis using adenosine monophosphate challenge

Clinical and Experimental Allergy

Volumn 37, Issue 5, 2007, Pages 696-703

  Barnes, M L ^a   Menzies, D ^a   Nair, A R ^a   Hopkinson, P J ^a   Lipworth, B J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Allergic; Dose response relationship; Drug; Fluticasone; Nasal provocation tests; Perennial; Reproducibility of results; Rhinitis

Indexed keywords

ADENOSINE PHOSPHATE; ANTIHISTAMINIC AGENT; CORTICOSTEROID; CREATININE; FLUTICASONE PROPIONATE; HYDROCORTISONE; NITRIC OXIDE; PLACEBO; STEROID;

ADRENAL SUPPRESSION; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; HYDROCORTISONE URINE LEVEL; INSPIRATORY CAPACITY; LOW DRUG DOSE; MALE; NOSE; PERENNIAL RHINITIS; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADENOSINE MONOPHOSPHATE; ADOLESCENT; ADULT; AGED; ANDROSTADIENES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; NASAL PROVOCATION TESTS; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME;

EID: 34247359618     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2007.02713.x     Document Type: Article

References (40)

1. Lee D, Gardiner M, Lipworth B. Comparative effects of desloratadine, fexofenadine and levocetirizine on nasal adenosine monophosphate in patients with perennial allergic rhinitis. Clin Exp Allergy 2004 34: 650 3.
2. Polosa R, Pagano C, Prosperini G et al. Histamine release upon adenosine 5′-monophosphate (AMP) nasal provocation in allergic subjects. Thorax 1999 54: 230 3.
3. Church MK, Holgate ST, Hughes PJ. Adenosine inhibits and potentiates IgE-dependent histamine release from human basophils by an A2-receptor mediated mechanism. Br J Pharmacol 1983 80: 719 26.
4. Polosa R, Ng WH, Crimi N et al. Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Am J Respir Crit Care Med 1995 151 (Part 1): 624 9.
5. Hughes PJ, Holgate ST, Church MK. Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A2-purinoceptor mediated mechanism. Biochem Pharmacol 1984 33: 3847 52.
6. Peachell PT, Columbo M, Kagey-Sobotka A, Lichtenstein LM, Marone G. Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis 1988 138: 1143 51.
7. van den Berge M, Meijer RJ, Kerstjens HA et al. PC(20) adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med 2001 163: 1546 50.
8. De Meer G, Heederik D, Postma DS. Bronchial responsiveness to adenosine 5′-monophosphate (AMP) and methacholine differ in their relationship with airway allergy and baseline FEV(1). Am J Respir Crit Care Med 2002 165: 327 31.
9. van den Berge M, Kerstjens HA, Postma DS. Provocation with adenosine 5′-monophosphate as a marker of inflammation in asthma, allergic rhinitis and chronic obstructive pulmonary disease. Clin Exp Allergy 2002 32: 824 30.
10. de Meer G, Marks GB, Postma DS. Direct or indirect stimuli for bronchial challenge testing: what is the relevance for asthma epidemiology? Clin Exp Allergy 2004 34: 9 16.
11. Wilson AM, Sims EJ, Orr LC, Robb F, Lipworth BJ. An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge. Br J Clin Pharmacol 2003 55: 354 9.
12. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001 31: 616 24.
13. Wilson AM, Orr LC, Sims EJ, Dempsey OJ, Lipworth BJ. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000 162 (Part 1): 1297 301.
14. Lee DK, Jackson CM, Soutar PC, Fardon TC, Lipworth BJ. Effects of single or combined histamine H1-receptor and leukotriene cyslt1-receptor antagonism on nasal adenosine mono phosphate challenge in persistent allergic rhinitis. Br J Clin Pharmacol 2004 57: 714 9.
15. Lee DK, Gardiner M, Haggart K, Fujihara S, Lipworth BJ. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004 34: 650 3.
16. Lee DK, Gray RD, Robb FM, Fujihara S, Lipworth BJ. A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. Clin Exp Allergy 2004 34: 646 9.
17. Lee DK, Carstairs IJ, Haggart K, Jackson CM, Currie GP, Lipworth BJ. Butterbur, a herbal remedy, attenuates adenosine monophosphate induced nasal responsiveness in seasonal allergic rhinitis. Clin Exp Allergy 2003 33: 882 6.
18. Wright JG, Young NL. A comparison of different indices of responsiveness. J Clin Epidemiol 1997 50: 239 46.
19. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987 40: 171 8.
20. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcomes measures for use in clinical trials. Health Technol Assess 1998 2. Available free from
21. Johansen LV, Illum P, Kristensen S, Winther L, Vang Petersen S, Synnerstad B. The effect of budesonide (Rhinocort) in the treatment of small and medium-sized nasal polyps. Clin Otolaryngol Allied Sci 1993 18: 524 7.
22. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000 30: 132 40.
23. Payne DN. Nitric oxide in allergic airway inflammation. Curr Opin Allergy Clin Immunol 2003 3: 133 7.
24. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005 171: 912 30.
25. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997 52: 476 82.
26. Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic evaluation. Med Care 1990 28: 632 42.
27. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 (Suppl.): S147 334.
28. Malm L, Gerth van Wijk R, Bachert C. Guidelines for nasal provocations with aspects on nasal patency, airflow, and airflow resistance. International committee on objective assessment of the nasal airways, international rhinologic society. Rhinology 2000 38: 1 6.
29. Wilson A, Orr L, Robb R, Sims E. Reproducibility of nasal function measurements with histamine and adenosine monophosphate nasal challenge testing in patients with allergic rhinitis. Allergol Int 2003 52: 155 60.
30. Litvyakova LI, Baraniuk JN. Nasal provocation testing: a review. Ann Allergy Asthma Immunol 2001 86: 355 64, quiz 364-5, 386.
31. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986 1: 307 10.
32. Beaton DE, Bombardier C, Katz JN, Wright JG. A taxonomy for responsiveness. J Clin Epidemiol 2001 54: 1204 17.
33. Sims EJ, Wilson AM, White PS, Gardiner Q, Lipworth BJ. Short-term repeatability and correlates of laboratory measures of nasal function in patients with seasonal allergic rhinitis. Rhinology 2002 40: 66 8.
34. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2000 85: 111 4.
35. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001 31: 61 8.
36. Skoner DP, Rachelefsky GS, Meltzer EO et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000 105: E23.
37. Skoner DP, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003 90: 56 62.
38. Wilson AM, McFarlane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol 1998 101 (Part 1): 470 4.
39. Wilson AM, Sims EJ, McFarlane LC, Lipworth BJ. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998 102 (Part 1): 598 604.
40. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002 360: 1715 21.